Abstract
Purpose. To characterize the in vivo specific binding andpharmacokinetics of a 1,4-dihydropyridine (DHP) calcium channel antagonist, PN200-110, in the senescent brain, using senescence-accelerated pronemice (SAMP8) and senescence-resistant mice (SAMR1).
Methods. Blood, brain, and heart samples were taken periodically fromSAMR1 and SAMP8 following intravenous injection of (+)-[3H]PN200-110, and the concentration of (+)-[3H]PN 200-110 in the plasmaand tissues was determined. In addition, the in vivo specific bindingof (+)-[3H]PN 200-110 in the brains of SAMR1 and SAMP8 wasmeasured periodically after intravenous injection of the radioligand.
Results. There was very little significant difference between SAMR1and SAMP8 in terms of the half-life (t1/2), total body clearance (CLtot),steady-state volume of distribution (Vdss), and AUC for the plasmaconcentration of (+)-[3H]PN 200-110 after intravenous injection ofthe radioligand. The brain concentration (AUCbrain) for (+)-[3H]PN200-110 and the brain/plasma AUC ratio (AUCbrain/AUCplasma) weresignificantly lower in SAMP8 than in SAMR1, and the heartconcentration (AUCheart) and the heart/plasma AUC ratio (AUCheart/AUCplasma)were similar in both strains. Also, the brain/plasma unbound AUCratio (AUCbrain/AUCplasma-free) for (+)-[3H]PN 200-110 wassignificantly lower in SAMP8 than in SAMR1. The in vivo specific binding(AUCspecific binding, maximal number of binding sites: Bmax) of(+)-[3H]PN 200-110 was significantly lower in brain particulate fractionsof SAMP8 than SAMR1.
Conclusions. The concentration and in vivo specific binding of(+)-[3H]PN 200-110 was significantly reduced in the senescent brain. Thesimultaneous analysis of the concentrations of centrally acting drugsand the in vivo specific binding in the brain in relation to theirpharmacokinetics may be valuable in evaluating their CNS effects.
Similar content being viewed by others
REFERENCES
T. Takeda, M. Hosokawa, S. Takeshita, M. Irino, K. Higuchi, T. Matsushita, Y. Tomita, K. Yasuhira, H. Hamamoto, K. Shimizu, M. Ishii, and T. Yamamuro. A new murine model of accelerated senescence. Mech. Aging Dev. 17:183–194 (1981).
M. Miyamoto, Y. Kiyota, N. Yamazaki, A. Nagaoka, T. Matsuo, Y. Nagama, and T. Takeda. Age-related changes in learning and memory in the senescence-accelerated mouse (SAM). Physiol. Behav. 38:399–406 (1986).
H. Yagi, S. Katoh, I. Akiguchi, and T. Takeda. Age-related deterioration of ability of acquisition in memory and learning in senescence accelerated mouse: SAM-P/8 as an animal model of disturbances in recent memory. Brain Res. 474:86–93 (1988).
K. Higuchi, A. Matsumura, A. Honma, S. Takeshita, K. Hashimoto, M. Hosokawa, K. Yasuhira, and T. Takeda. Systemic senile amyloid in senescence-accelerated mouse. A unique fibril protein demonstrated in tissues from various organs by unlabeled immunoperoxidase method. Lab. Invest. 48:231–240 (1983).
Y. Kitamura, X.-H. Zhao, T. Ohnuki, and Y. Nomura. Ligand-binding characteristics of [ 3 H]QNB, [ 3 H]prazosin, [ 3 H]rauwolscine, [ 3 H]TCP and [ 3 H]nitrendipine to cerebral cortical and hippocampal membranes of senescence accelerated mouse. Neurosci. Lett. 106:334–338 (1989).
H. Kabuto, T. Yokoi, A. Mori, M. Murakami, and S. Sawada. Neurochemical changes related to ageing in the senescence-accelerated mouse brain and the effect of chronic administration of nimodipine. Mech. Aging Dev. 80:1–9 (1995).
S. Yamada, S. Uchida, T. Ohkura, R. Kimura, M. Yamaguchi, M. Suzuki, and M. Yamamoto. Alterations in calcium antagonist receptors and calcium content in senescent brain and attenuation by nimodipine and nicardipine. J. Pharmacol. Exp. Ther. 277:721–727 (1996).
P. K. Fischhof. Divergent neuroprotective effects of nimodipine in PDD and MID provide indirect evidence of disturbances in Ca 2+ homeostasis in dementia. Mech. Find. Exp. Clin. Pharmacol. 15:549–555 (1993).
J. G. Kelly and O'Malley. Calcium antagonists in the elderly. Drugs Aging 3:400–407 (1993).
H. F. Schran, J. M. Jaffe, and L. M. Gonasum. Clinical pharmacokinetics of isradipine. Am. J. Med. 84(suppl. 3B):80–89 (1988).
F. L. S. Tse, J. M. Jaffe, A. E. Hassell, and H. F. Schran. Bioavailability of isradipine in young and old rats: effect of mode of administration. J. Pharm. Pharmacol. 41:657–660 (1989).
Y. Tokuma, T. Fujiwara, and H. Noguchi. Absorption, distribution and excretion of nilvadipine, a new dihydropyridine calcium antagonist, in rats and dogs. Xenobiotica 17:1341–1349 (1987).
S. Yamada, Y. Matsuoka, Y. Kato, R. Kimura, and O. Inagaki. A sustained occupancy in vivo of cardiovascular calcium antagonist receptors by mepirodipine and its relation to pharmacodynamic effect in spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 262:589–594 (1992).
S. Uchida, S. Yamada, T. Ohkura, M. Heshikiri, A. Yoshimi, H. Shirahase, and R. Kimura. The receptor occupation and plasma concentration of NKY-722, a water-soluble dihydropyridine-type calcium antagonist, in spontaneously hypertensive rats. Br. J. Pharmacol. 114:217–223 (1995).
K. Yamaoka, Y. Tanigawara, T. Nakagawa, and T. Uno. A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobiodyn. 4:879–885 (1981).
R. Weizman, A. Weizman, K. A. Kook, F. Vocci, S. I. Deutsh, and S. M. Paul. Repeated swim stress alters brain benzodizepine receptors measured in vivo. J. Pharmacol. Exp. Ther.bd249:701–707 (1989).
T. M. Jay, G. Lucignani, A. M. Crane, J. Jehle, and L. Sokoloff. Measurement of local cerebral blood flow with [ 14 C]iodoantipyrine in the mouse. J. Cereb. Blood Flow Metab. 8:121–129 (1988).
M. Gibaldi and D. Perrier. Pharmacokinetics (2nd Ed.), Marcel Dekker Inc., New York, Basel, 1982.
M. A. Gonzales, T. N. Tozer, and D. T. T. Chang. Nonlinear tissue disposition: salicylic acid in rat brain. J. Pharm. Sci. 64:99–103 (1975).
M. A. Hedeya and R. J. Sawchuk. Effect of probenecid on the renal and nonrenal clearances of zidovudine and its distribution into cerebrospinal fluid in the rabbit. J. Pharm Sci. 78:716–722 (1989).
D. S. Heffez, T. S. Nowak, and J. V. Passoneau. Nimodipine levels in gerbil brain following parenteral drug administration. J. Neurosurg. 63:589–592 (1985).
S. Uchida, S. Yamada, K Nagai, Y. Deguchi, and R. Kimura. Brain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyrine calcium channel antagonists. Life Sci. 61:2083–2090 1997).
M. Ueno, I. Akiguchi, H. Yagi, M. Takemura, T. Kitabayashi, J. Kimura, M. Hosokawa, and T. Takeda. In T. Takeda (eds.), Age-related changes in blood-brain barrier of the SAM brain. The SAM Model of Senescence, Elsevier Science B. V., 1994, pp. 327–330.
M. M. Cornwell, I. Pastan, and M. M. Gottesman. Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J. Biol. Chem. 262:2166–2170 (1987).
I. Tamai and A. R. Safa. Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistance cells. J. Biol. Chem. 266:16796–16800 (1991).
A. Tsuji, T. Terasaki, Y. Takabataka, Y. Tenda, I. Tamai, T. Yamashima, S. Moritani, T. Tsuruo, and J. Yamashita. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci. 51:1427–1437 (1992).
S. Gupta. P-glycoprotein expression and regulation: age-related changes and potential effects on drug therapy. Drugs Aging. 7:19–29 (1995).
M. D. Hollenberg. Examples of homospecific and heterospecific receptor regulation. Trends Pharmacol. Sci. 6:242–245 (1985).
J. Cahn and M. G. Borzweix. Water, electrolytes contents of the brain and cerebral function in aged rats. Monogr. Neural Sci. 11:85–92 (1984).
M. A. Piggott, J. M. Candy, and R. H. Perry. [ 3 H]Nitrendipine binding in temporal cortex in Alzheimer's and Huntington's diseases. Brain Res. 565:42–47 (1991).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Uchida, S., Yamada, S., Deguchi, Y. et al. In Vivo Specific Binding Characteristics and Pharmacokinetics of a 1,4-Dihydropyridine Calcium Channel Antagonist in the Senescent Mouse Brain. Pharm Res 17, 844–850 (2000). https://doi.org/10.1023/A:1007512426420
Issue Date:
DOI: https://doi.org/10.1023/A:1007512426420